Risultati per: Tumore prostata, test della saliva piu’ attendibile del PSA

Terapia CAR-T a Bambino Gesù, 36% senza tracce malattia a 3 anni

Terapia CAR-T a Bambino Gesù, 36% senza tracce malattia a 3 anni

Operazione di quattro ore al Policlinico di Milano, già dimessa

L’appello sui social dell’attore: “Mettete sempre la crema solare”

Grazie alla Biopsia Fusion, con 100 mila euro di investimento

Annals of Internal Medicine, Ahead of Print.

Gli esperti, servono nuove regole nella gestione del follow-up

To the Editor In their recent systematic review and meta-analysis in JAMA Oncology, Mukhopadhyay et al compare 3 statistical tests based on historic immuno-oncology trials with registrational intent. Unsurprisingly, they conclude that the so-called MaxCombo test has higher power to demonstrate a treatment difference. However, they misleadingly cite one of our articles, claiming that this test controls the type I error. On the contrary, our publications demonstrate that MaxCombo is not valid to show benefit of a candidate drug. A better alternative to the standard log-rank test is the modestly weighted test.

In Reply We would like to thank Magirr and Burman for their thoughtful comments on our systematic review and meta-analysis and will address some of their concerns.

The clinical course of IBD varies considerably among patients1. One barrier to personalized medicine in IBD is the lack of a reliable prognostic assay that can be used at diagnosis to guide effective therapy for each patient, to optimize clinical outcomes and minimize complications. To address this need, a whole-blood qPCR-based prognostic assay was developed to divide IBD patients into two subgroups2. This transcriptional signature yields CD8 T-cell exhaustion level data that correlated with disease outcomes among IBD patients in UK2.

Al Bambino Gesù, la piccola pesava 8 kg.Ora ha 1 anno e sta bene

Al Bambino Gesù, la piccola pesava 8 kg.Ora ha 1 anno e sta bene

Centro ricerche Altamedica,individua mutazioni geniche collegate

Procedura indolore dura 10 minuti, test positivo su 2 pazienti

In late February, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization to an at-home diagnostic test that identifies SARS-CoV-2, the virus that causes COVID-19, as well as influenza strains A and B. The test detected 100% of negative and 88.3% of positive COVID-19 samples, 99.3% of negative and 90% of positive influenza A samples, and 99.9% of negative influenza B samples.

Circulation, Volume 147, Issue 12, Page 987-987, March 21, 2023.